Titrating droxidopa to maximize symptomatic benefit in a patient with Parkinson disease and neurogenic orthostatic hypotension (vol 27, pg S15, 2017)

被引：0

作者：

Gupta, Fiona ^{[1
]}

Karabin, Beverly ^{[2
]}

Mehdirad, Ali ^{[3
,4
]}

机构：

[1] Hackensack Univ, Med Ctr, Movement Disorders Ctr, Hackensack, NJ USA

[2] Univ Toledo, Syncope & Auton Disorders Ctr, 2801 W Bancroft St, Toledo, OH 43606 USA

[3] St Louis Univ, Dept Internal Med, Div Cardiol, Cardiac Electrophysiol Sect, St Louis, MO USA

[4] St Louis Univ, Dept Internal Med, St Louis, MO USA

来源：

CLINICAL AUTONOMIC RESEARCH | 2017年 / 27卷 / 06期

关键词：

D O I：

10.1007/s10286-017-0458-y

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

引用

页码：431 / 431

页数：1

共 30 条

[21] Droxidopa Treatment Impact on Orthostatic Symptoms and Standing Systolic Blood Pressure in Patients with Parkinson's Disease (PD) and Symptomatic Neurogenic Orthostatic Hypotension (NOH)
Isaacson, Stuart
Hauser, Robert
Szakacs, Cameron
Cioffi, Christopher
NEUROLOGY, 2013, 80 (19) : E203 - E203
[22] Impact of droxidopa treatment on falls and fall related injuries in patients with Parkinson's disease and symptomatic neurogenic orthostatic hypotension (study 306)
Hauser, R. A.
Jerome, L. P.
Schwieterman, W. D.
Cioffi, C. C.
MOVEMENT DISORDERS, 2013, 28 : S171 - S171
[23] Treatment of Orthostatic Hypotension Due to Autonomic Dysfunction (Neurogenic Orthostatic Hypotension) in a Patient with Cardiovascular Disease and Parkinson's Disease
McCullough, Peter A.
CARDIOLOGY AND THERAPY, 2019, 8 (01) : 145 - 150
[24] Treatment of Orthostatic Hypotension Due to Autonomic Dysfunction (Neurogenic Orthostatic Hypotension) in a Patient with Cardiovascular Disease and Parkinson's Disease
Peter A. McCullough
Cardiology and Therapy, 2019, 8 : 145 - 150
[25] Fall-related healthcare use and costs in neurogenic orthostatic hypotension with Parkinson's disease (vol 20, pg 525, 2017)
Francois, C.
Biaggioni, I
Shibao, C.
Ogbonnaya, A.
Shih, H-C
Farrelly, E.
Ziemann, A.
Duhig, A.
JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (11) : 1216 - 1216
[26] Safety and efficacy of droxidopa (Norther™) for the treatment of symptomatic neurogenic orthostatic by (NOH) in patients with Parkinson's disease (PD)
Mathias, C. J.
Kaufmann, H.
MOVEMENT DISORDERS, 2010, 25 (07) : S405 - S406
[27] Long-term evaluation of 24 hour ambulatory blood pressure monitoring in patients with Parkinson's disease and symptomatic neurogenic orthostatic hypotension treated with droxidopa
Brillman, S.
Husain, S.
Isaacson, S. H.
MOVEMENT DISORDERS, 2015, 30 : S72 - S73
[28] Falls During a 10-week Placebo-Controlled Study of Droxidopa for Neurogenic Orthostatic Hypotension in Parkinson's Disease
Rowse, G.
Heritier, S.
Hewitt, L.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2015, 63 : S31 - S31
[29] Characteristics of orthostatic hypotension in Parkinson's disease (Retraction of vol 130, pg 2425, 2007)
Oka, H.
Yoshioka, M.
Onouchi, K.
Morita, M.
Mochio, S.
Suzuki, M.
BRAIN, 2008, 131 : 1674 - 1674
[30] RETRACTED: Characteristics of orthostatic hypotension in Parkinson's disease (Retracted Article. See vol 131, pg 1674, 2008)
Oka, Hisayoshi
Yoshioka, Masayuki
Onouchi, Kenji
Morita, Masayo
Mochio, Soichiro
Suzuki, Masahiko
Hirai, Toshiaki
Ito, Yasuhiko
Inoue, Kiyoharu
BRAIN, 2007, 130 : 2425 - 2432

← 1 2 3 →